---
title: "MustGrow publishes investor presentation on mustard-derived biological crop protection products"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295689537.md"
description: "MustGrow Biologics Corp. released an investor presentation detailing commercialization plans for mustard-derived biological crop inputs, including TerraSante biofertility and TerraMG biocontrol. TerraSante is already registered in key U.S. states with 2025 supply sold out. TerraMG targets registrations in Canada and the U.S. by 2026/2027. The company holds an exclusive Bayer license for EMEA biocontrol rights. Financial data cited includes a market cap of CAD 30 million and cash reserves of CAD 419,577 as of March 31, 2026."
datetime: "2026-08-12T16:09:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295689537.md)
  - [en](https://longbridge.com/en/news/295689537.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295689537.md)
generator: "portal-rs"
---

# MustGrow publishes investor presentation on mustard-derived biological crop protection products

-   MustGrow outlined commercialization plans for mustard-derived biological crop inputs spanning biofertility, biocontrol, postharvest, and animal health applications. \* TerraSante biofertility targets U.S. high-value crops; product registered in key states; 2025 supply sold out with about 1,000 acres applied. \* TerraMG biocontrol registrations targeted for 2026⁄2027 in Canada and the U.S.; positioned as an organic alternative to soil fumigants. \* Exclusive Bayer license covers EMEA biocontrol registration; MustGrow expects upfront and milestone payments, then royalties after registration. \* Presentation cited 70,441,359 shares outstanding; fully diluted 91,914,368; market cap CAD 30 million; cash CAD 419,577 at March 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md)
- [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md)
- [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md)

## Related News & Research

- [Bayer says Japan approves sevabertinib for HER2-mutant NSCLC](https://longbridge.com/en/news/296745277.md)
- [MustGrow Biologics publishes corporate presentation on mustard-derived biologicals for regenerative agriculture](https://longbridge.com/en/news/291834171.md)
- [Do I Have Thoughts About Crop Tours?](https://longbridge.com/en/news/296134865.md)
- [BioSyent GAAP EPS of C$0.25, revenue of C$19.87M](https://longbridge.com/en/news/296538491.md)
- [1 Trade to Make as the Pro Farmer Crop Tour Wraps Up](https://longbridge.com/en/news/296505446.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**